TR201821021T4 - Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar. - Google Patents
Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar. Download PDFInfo
- Publication number
- TR201821021T4 TR201821021T4 TR2018/21021T TR201821021T TR201821021T4 TR 201821021 T4 TR201821021 T4 TR 201821021T4 TR 2018/21021 T TR2018/21021 T TR 2018/21021T TR 201821021 T TR201821021 T TR 201821021T TR 201821021 T4 TR201821021 T4 TR 201821021T4
- Authority
- TR
- Turkey
- Prior art keywords
- cancer
- claudin
- cancer treatment
- expression antibodies
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102000003859 Claudin-6 Human genes 0.000 title 1
- 108090000229 Claudin-6 Proteins 0.000 title 1
- 206010004593 Bile duct cancer Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 102100038449 Claudin-6 Human genes 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010073069 Hepatic cancer Diseases 0.000 abstract 1
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025598 Malignant hydatidiform mole Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract 1
- 206010057644 Testis cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 208000026900 bile duct neoplasm Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000008824 placental choriocarcinoma Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 201000003120 testicular cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Mevcut buluş, over kanseri, akciğer kanseri, mide kanseri, meme kanseri, hepatik kanser, pankreas kanseri, cilt kanseri, habis melanom gibi tümöre bağlı hastalıklar, baş boyun kanseri, sarkom, safra kanalı kanseri, idrar kesesi kanseri, böbrek kanseri, kolon kanseri, plasental koriokarsinom, rahim ağzı kanseri, testis kanseri ve uterin kanseri gibi, CLDN6 ifade eden hücrelerle ilişkili hastalıkların tedavisi ve/veya önlenmesi için terapötikler olarak faydalı antikorlar sunmaktadır.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161486071P | 2011-05-13 | 2011-05-13 | |
EP11004004 | 2011-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201821021T4 true TR201821021T4 (tr) | 2019-01-21 |
Family
ID=65681287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2018/21021T TR201821021T4 (tr) | 2011-05-13 | 2012-04-20 | Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar. |
Country Status (7)
Country | Link |
---|---|
JP (2) | JP6748282B2 (tr) |
KR (1) | KR102128027B1 (tr) |
ES (1) | ES2703936T3 (tr) |
HU (1) | HUE041781T2 (tr) |
PT (1) | PT3026064T (tr) |
SG (1) | SG10201911551RA (tr) |
TR (1) | TR201821021T4 (tr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0907237A2 (pt) * | 2008-01-11 | 2015-07-14 | Univ Tokyo | Anticorpo anti-cldn6 |
NO2499161T3 (tr) * | 2009-11-11 | 2018-02-03 |
-
2012
- 2012-04-20 ES ES15201110T patent/ES2703936T3/es active Active
- 2012-04-20 PT PT15201110T patent/PT3026064T/pt unknown
- 2012-04-20 KR KR1020207002280A patent/KR102128027B1/ko active IP Right Grant
- 2012-04-20 HU HUE15201110A patent/HUE041781T2/hu unknown
- 2012-04-20 SG SG10201911551RA patent/SG10201911551RA/en unknown
- 2012-04-20 TR TR2018/21021T patent/TR201821021T4/tr unknown
-
2019
- 2019-12-19 JP JP2019228917A patent/JP6748282B2/ja active Active
-
2020
- 2020-08-06 JP JP2020133736A patent/JP7263294B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6748282B2 (ja) | 2020-08-26 |
KR102128027B1 (ko) | 2020-06-30 |
HUE041781T2 (hu) | 2019-05-28 |
ES2703936T3 (es) | 2019-03-13 |
KR20200014436A (ko) | 2020-02-10 |
JP7263294B2 (ja) | 2023-04-24 |
JP2020063282A (ja) | 2020-04-23 |
PT3026064T (pt) | 2018-12-17 |
JP2020186257A (ja) | 2020-11-19 |
SG10201911551RA (en) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121085T1 (el) | Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6 | |
CY1123192T1 (el) | Αντισωματα ειδικα στην κλαουδινη 6 (cldν6) | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
BR112019017743A2 (pt) | rna terapêutico | |
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
EP4218832A3 (en) | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
TN2016000577A1 (en) | Anti-cdh6 antibody drug conjugates | |
MX2019009441A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2019013723A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2013010475A (es) | Composiciones inmunoterapeuticas de levadura-brachyuri. | |
CY1120123T1 (el) | Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου | |
WO2015106273A3 (en) | Methods and assays relating to huntingtons disease and parkinson's disease | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
EP3736022A3 (en) | Treatment and diagnosis of colon cancer | |
EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
TR201821021T4 (tr) | Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar. | |
TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. |